NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of RxSight, Inc. (NASDAQ: RXST) between November 7, 2024 and July 8, 2025, both dates inclusive (the “Class Period”, of the important September 22, 2025 lead plaintiff deadline. SO WHAT: If you purchased RxSight securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT ...

SAN DIEGO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that the RxSight class action lawsuit – captioned Makaveev v. RxSight, Inc., No. 25-cv-01596, and pending in the Central District of California – seeks to represent purchasers or acquirers of RxSight, Inc. (NASDAQ: RXST) securities and charges RxSight as well as certain of RxSight’s top executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintif ...

NEW YORK, Aug. 1, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in RxSight, Inc. ("RxSight, Inc." or the "Company") (NASDAQ: RXST) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of RxSight, Inc. investors who were adversely affected by alleged securities fraud between November 7, 2024 and July 8, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/rxsight-inc-lawsuit-submiss ...

NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in RxSight, Inc. ("RxSight, Inc." or the "Company") (NASDAQ: RXST) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of RxSight, Inc. investors who were adversely affected by alleged securities fraud between November 7, 2024 and July 8, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/rxsight-inc-lawsuit- ...

证券欺诈集体诉讼 - 投资者因RxSight公司证券欺诈遭受重大损失 有机会成为集体诉讼的首席原告 [1] - 诉讼指控公司在2024年11月7日至2025年7月8日期间未披露销售下滑和产品需求被夸大等问题 [3] - 公司此前发布的2025财年财务指引可能无法实现 导致管理层关于业务前景的陈述存在误导性 [3] 诉讼核心指控 - 公司面临产品"采用挑战"和结构性难题 导致销售额和使用率下降 [3] - 管理层对RxSight产品需求的表述存在夸大成分 [3] - 上述问题使得公司2025财年业绩指引失去实现基础 [3] 投资者参与方式 - 受损投资者需在2025年9月22日前联系Howard G Smith律师事务所 [2] - 投资者可选择自行聘请律师或保持缺席成员身份参与集体诉讼 [5] - 律师事务所提供电话、邮件和网站等多种联系方式供投资者咨询 [4][6]

SAN DIEGO, July 30, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired RxSight, Inc. (NASDAQ: RXST) securities between November 7, 2024 and July 8, 2025. RxSight is a commercial-stage medical technology company, engaged in the research and development, manufacture, and sale of light adjustable intraocular lenses ("LAL") used in cataract surgery in the United States. The Company's primary product is the RxSight system ...

NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against RxSight, Inc. (NASDAQ: RXST) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in RxSight, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/rxsight-inc-class-action-lawsuit. Investors have until September 22, 2025, to ask the Court to ...

公司概况 - RxSight是一家位于加州Aliso Viejo的医疗技术公司 专注于开发用于白内障手术的光可调节人工晶体(LAL) 其核心产品为RxSight系统中的光传输设备(LDD) [2] 诉讼核心指控 - 公司被指控在2024年11月7日至2025年7月8日期间未向投资者披露：1) 产品面临"采用挑战"和结构性销售下滑问题 2) 夸大产品需求 3) 无法实现2025财年既定财务目标 [3] - 2025年7月8日公司公告显示：LDD设备销量 LAL使用率和整体收入在2025年第二季度显著下降 同时下调2025全年收入指引 [4] - CEO Ronald Kurtz承认"过去几个季度的采用挑战是LDD销售停滞的主要原因" [4] 市场反应 - 负面公告导致次日(2025年7月9日)股价单日暴跌4.84美元(37%) 收盘价报7.95美元/股 [4] 法律程序 - 集体诉讼代表资格申请截止日为2025年9月22日 涵盖2024年11月7日至2025年7月8日期间购入公司证券的投资者 [1][2]

SAN DIEGO, July 29, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that the RxSight class action lawsuit – captioned Makaveev v. RxSight, Inc., No. 25-cv-01596 (C.D. Cal.) – seeks to represent purchasers or acquirers of RxSight, Inc. (NASDAQ: RXST) securities and charges RxSight as well as certain of RxSight's top executives with violations of the Securities Exchange Act of 1934.If you suffered substantial losses and wish to serve as lead plaintiff of the RxSight class actio ...

诉讼调查 - 律师事务所Faruqi & Faruqi正在调查RxSight公司潜在的证券法违规行为 并提醒投资者在2025年9月22日前申请成为集体诉讼的首席原告 [2] - 调查涉及RxSight在2024年11月7日至2025年7月8日期间可能存在的虚假陈述或信息披露不充分问题 [1][4] - 律师事务所自1995年成立以来已为投资者追回数亿美元损失 在纽约 宾夕法尼亚 加利福尼亚和乔治亚州设有办公室 [3] 公司财务问题 - RxSight在2025年第二季度财报中披露LDD销售额 LAL使用率和整体收入显著下降 并将2025年全年指引中值下调约4250万美元 [5] - 公司CEO承认"过去几个季度的采用挑战"是LDD销售停滞的主要原因 [5] - 财报公布后次日 公司股价单日暴跌4.84美元(37.8%)至7.95美元 成交量异常放大 [5] 指控内容 - 指控称RxSight未如实披露公司面临"采用挑战"和结构性问题 导致销售和使用率下降 [4] - 公司被指控夸大产品需求 且不太可能实现其先前发布的2025财年财务指引 [4] - 指控认为公司高管关于业务运营和前景的积极陈述存在重大误导性且缺乏合理依据 [4] 法律程序 - 法院将指定在索赔中具有最大财务利益的投资者作为首席原告 该原告需能代表集体诉讼成员的利益 [6] - 集体诉讼成员可选择自行聘请律师申请担任首席原告 或选择不作为而保留缺席成员身份 [6] - 律师事务所呼吁了解RxSight行为的知情人士(包括举报人 前员工 股东等)提供信息 [7]